The Tachi Ya­ma­da lega­cy tree con­tin­ues to grow with a new gene edit­ing biotech from Jim Wil­son

Jim Wil­son has been busy late­ly.

Back in May, the AAV pi­o­neer from the Uni­ver­si­ty of Penn­syl­va­nia launched a sec­ond-gen­er­a­tion gene ther­a­py biotech, G2 Bio …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.